Glioblastoma multiforme (GBM) is the most common, complex, treatment resistant, and deadliest type of brain cancer, accounting for 45% of all brain cancers, with nearly 11,000 men, women, and children diagnosed each year. The time is now to make progress against this disease!
The Defeat GBM Research Collaborative is a groundbreaking, research-based initiative that takes advantage of the convergence of exciting scientific advancements, an innovative business model, and support from biopharmaceutical companies to drive research forward with the aim of doubling the five-year survival rate of GBM patients. Building from the pioneering data discovered through The Cancer Genome Atlas (TCGA) and the growing commitment to true collaboration across disciplines and institutions, we have entered a new era of possibilities. All members of the Defeat GBM Research Collaborative share real-time information of one another’s cutting-edge research to quicken the pace of translating discoveries into clinical stage research—cutting years out of the traditional. Together with your support, we can bring change today!